NGNE - NASDAQ

Neurogene Inc.

NGNE·NASDAQ

$26.22

+0.31%

HealthcareBiotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$414.33M

EPS-4.2400

P/E Ratio-6.18

Earnings Date08/07/2026

288.60M

Assets

-14%

3Y+164.0%

5Y+37.0%

10Y+87.0%

23.72M

Total Liabilities

-6%

3Y+123.0%

5Y+23.0%

10Y+144.0%

264.89M

Total Equity

-15%

3Y+169.0%

5Y+39.0%

10Y+83.0%

Neurogene Inc. Funding & Solvency Profile

NGNE · NASDAQ

Current Assets

Cash & Cash Equivalents103.84M

Net Receivables0.00

Inventory0.00

Other Current Assets2.76M

Total Current Assets272 M

Non-Current Assets

Property, Plant & Equipment15.46M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.37M

Total Non-Current Assets17 M

Total Assets

288.60M

Financial Health Analysis

Current Ratio

16.56x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.09x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

255 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

94% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Neurogene Inc. Balance Sheet

NGNE • NASDAQ

Neurogene Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	103.8M	136.6M	148.2M	82M	70.5M	192.6M	143.1M	76.9M	52M	32.3M	39.5M	14.9M	54.1M	2M	9.2M
Short-Term Investments	165.2M	175.8M	48.9M	0.0	0.0	0.0	0.0	0.0	56.1M	70.8M	35M	24.2M	2.8M	0.0	0.0
Cash & Short-Term Investments	269M	312.4M	197.2M	82M	70.5M	192.6M	143.1M	76.9M	108.1M	103.1M	74.5M	39.1M	56.9M	2M	9.2M
Net Receivables	0.0	648K	600K	0.0	790K	0.0	0.0	0.0	0.0	0.0	32K	65.4K	27.9K	28.5K	219.6K
Other Receivables	0.0	648K	600K	0.0	790K	0.0	0.0	0.0	0.0	0.0	32K	65.4K	27.9K	28.5K	219.6K
Inventory	0.0	0.0	0.0	0.0	1.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	1.9M	1.5M	1.1M	1.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	64K	35K	27.6K
Other Current Assets	2.8M	981K	1.1M	1.6M	-1.2M	2M	503K	237K	740K	426K	282K	139K	0.0	0.0	0.0
Total Current Assets	271.8M	315.9M	200.3M	84.7M	74M	194.5M	143.6M	77.2M	108.8M	103.5M	74.8M	39.3M	57M	2.1M	9.5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	15.5M	18.5M	21M	24.5M	27.5M	13.7M	2.8M	400K	905K	849K	89K	104.7K	75.5K	157.8K	259.4K
Intangible Assets	0.0	0.0	0.0	0.0	128K	347K	567K	0.0	0.0	0.0	0.0	0.0	62.5K	85.3K	108K
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	128K	347K	567K	0.0	0.0	0.0	0.0	0.0	62.5K	85.3K	108K
Long-Term Investments	0.0	0.0	0.0	0.0	878K	0.0	0.0	0.0	0.0	50M	38.5M	2M	0.0	0.0	0.0
Other Non-Current Assets	1.4M	1.3M	1.3M	0.0	-1M	1.9M	30K	53K	599K	0.0	0.0	13.4K	1.6M	34.8K	30.1K
Total Non-Current Assets	16.8M	19.8M	22.2M	24.5M	27.5M	16M	3.4M	453K	1.5M	50.9M	38.5M	2.1M	1.7M	277.9K	397.5K
Total Assets	288.6M	335.7M	222.6M	109.3M	101.5M	210.5M	147M	77.6M	110.3M	154.4M	113.3M	41.4M	58.8M	2.3M	9.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2M	1.3M	2.6M	625K	5.6M	1.3M	1.6M	702K	0.0	0.0	0.0	734.2K	599.8K	188.5K	317.5K
Accounts Payable	2M	1.3M	2.6M	625K	5.6M	1.3M	1.6M	702K	0.0	0.0	0.0	734.2K	599.8K	188.5K	317.5K
Accrued Expenses	0.0	9.4M	10.8M	5.2M	3.3M	3.2M	1.2M	0.0	1.6M	1M	2.5M	0.0	247.7K	80.6K	117.1K
Short Term Debt	3.1M	3M	0.0	0.0	1.2M	708K	618K	0.0	0.0	0.0	0.0	0.0	250K	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	2.9M	702K	610K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	11.4M	1.4M	6.7M	167K	132K	2.6M	1.3M	3.9M	9.4M	8.5M	2.3M	4.5M	1.5M	116.3K	173.3K
Total Current Liabilities	16.4M	15.2M	23M	6.7M	10.9M	7.9M	4.7M	4.6M	11M	9.5M	4.8M	5.2M	2.6M	385.4K	607.9K
NON-CURRENT LIABILITIES
Long Term Debt	6.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	124K	72.3K	2M	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	313K	453K	150K	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	479K	769K	203K	0.0	177.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8M	1.1M	689.6K
Total Non-Current Liabilities	7.3M	10.2M	13.6M	4M	182.5M	11.4M	593K	319K	486K	197K	131K	72.3K	4.9M	1.1M	689.6K
Capital Lease Obligations	0.0	9.4M	16.3M	4.7M	5.2M	11.4M	593K	6K	33K	47K	7K	0.0	0.0	0.0	0.0
Total Liabilities	23.7M	25.4M	36.5M	10.6M	193.4M	19.3M	5.3M	4.9M	11.4M	9.7M	4.9M	5.3M	7.5M	1.5M	1.3M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	244.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	52M	47.9M
Common Stock	0.0	0.0	0.0	0.0	1K	0.0	0.0	0.0	0.0	0.0	0.0	11.0	10.0	534.8K	534.8K
Additional Paid-In Capital	0.0	572.7M	373.2M	5.1M	3.8M	524M	441.2M	302.8M	297.5M	293.1M	220M	125.6M	114.9M	0.0	0.0
Retained Earnings	-352.6M	-262.3M	-187.2M	-150.8M	-95.6M	-332.8M	-299.5M	-230.1M	-198.5M	-148.3M	-111.3M	-89.4M	-63.6M	-51.6M	-39.8M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-70K	-169K	-290K	-3.9K	0.0	0.0	0.0
Other Total Stockholders' Equity	617.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	264.9M	310.4M	186M	98.6M	-91.9M	191.2M	141.7M	72.7M	98.9M	144.7M	108.4M	36.1M	51.3M	874K	8.6M
Total Equity	264.9M	310.4M	186M	98.6M	-91.9M	191.2M	141.7M	72.7M	98.9M	144.7M	108.4M	36.1M	51.3M	874K	8.6M
SUMMARY
Total Liabilities & Equity	288.6M	335.7M	222.6M	109.3M	101.5M	210.5M	147M	77.6M	110.3M	154.4M	113.3M	41.4M	58.8M	2.3M	9.9M
Total Investments	165.2M	175.8M	48.9M	0.0	878K	0.0	0.0	0.0	56.1M	120.8M	73.4M	26.2M	2.8M	0.0	0.0
Total Debt	9.9M	12.4M	16.3M	4.7M	6.4M	12.1M	1.2M	6K	33K	47K	131K	72.3K	2.3M	0.0	0.0
Net Debt	-94M	-124.2M	-132M	-77.3M	-64.1M	-180.4M	-141.9M	-76.9M	-52M	-32.3M	-39.4M	-14.8M	-51.8M	-2M	-9.2M
Shares Outstanding	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916	14,271,916

SEC Filings

NGNE - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 20, 2026	April 20, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 16, 2026	June 03, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 13, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing

Showing 1 to 10 of 224 filings

Related Guides

Blog Categories

Continue your NGNE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.